Intellia Therapeutics Stock Price, News & Analysis (NASDAQ:NTLA)

$25.95 +1.01 (+4.05 %)
(As of 02/22/2018 08:06 AM ET)
Previous Close$24.94
Today's Range$25.02 - $27.25
52-Week Range$11.15 - $33.34
Volume890,600 shs
Average Volume922,229 shs
Market Capitalization$899.98 million
P/E Ratio-16.63
Dividend YieldN/A
Beta3.6

About Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics logoIntellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTLA
CUSIPN/A
Phone857-285-6200

Debt

Debt-to-Equity RatioN/A
Current Ratio8.88%
Quick Ratio8.88%

Price-To-Earnings

Trailing P/E Ratio-16.6346153846154
Forward P/E Ratio-15.45
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.48 million
Price / Sales56.83
Cash FlowN/A
Price / CashN/A
Book Value$5.83 per share
Price / Book4.45

Profitability

Trailing EPS($1.56)
Net Income$-31,630,000.00
Net Margins-215.92%
Return on Equity-28.01%
Return on Assets-19.83%

Miscellaneous

Employees104
Outstanding Shares36,090,000

Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics Inc (NASDAQ:NTLA) announced its quarterly earnings data on Tuesday, October, 31st. The company reported ($0.44) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.50) by $0.06. The business had revenue of $7.30 million for the quarter, compared to analyst estimates of $5.83 million. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The company's revenue was up 49.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.22) EPS. View Intellia Therapeutics' Earnings History.

Where is Intellia Therapeutics' stock going? Where will Intellia Therapeutics' stock price be in 2018?

7 brokers have issued twelve-month price objectives for Intellia Therapeutics' stock. Their forecasts range from $20.00 to $42.00. On average, they expect Intellia Therapeutics' stock price to reach $30.17 in the next twelve months. View Analyst Ratings for Intellia Therapeutics.

What are Wall Street analysts saying about Intellia Therapeutics stock?

Here are some recent quotes from research analysts about Intellia Therapeutics stock:

  • 1. According to Zacks Investment Research, "Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. " (10/4/2017)
  • 2. Cann analysts commented, "Loss per share was $0.45 compared to our estimated loss of $0.39. This was the result of lower than expected Collaborative revenue of $5.9 million compared to our estimate of $6.5 million and higher than estimated R&D expenses of $15.6 million compared to our estimated $14.1 million. Lower revenue and higher expenses were partially offset by a higher than estimated shares outstanding. There were no other meaningful variances in the quarter. Our outlook remains basically unchanged. We have made modest adjustments to our estimated shares outstanding and R&D expense." (8/1/2017)
  • 3. Chardan Capital analysts commented, "We initiate coverage of Intellia Therapeutics (NTLA) with a Buy rating (PT $19), on our view of possible downside driven by the company's IP weakness overridden by relative under-valuation of the CRISPR sector. Intellia is a preclinical biotech company aiming to treat various genetic conditions using the CRISPR-Cas9 gene editing system, in which a CRISPR guide RNA (gRNA) targets a Cas9 nuclease (a sort of "DNA scissors") to specifically modify a particular DNA sequence to treat diseases. Intellia's lead asset for transthyretin (TTR) amyloidosis, partnered with Neutral-rated Regeneron Pharmaceuticals, is guided to initiate IND-enabling studies by 2H17/1H18." (3/27/2017)

Who are some of Intellia Therapeutics' key competitors?

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the folowing people:

  • Perry A. Karsen, Chairman of the Board (Age 62)
  • John M. Leonard M.D., President, Chief Executive Officer (Age 59)
  • Graeme Bell, Chief Financial Officer, Executive Vice President (Age 50)
  • Jose E. Rivera J.D., Executive Vice President, General Counsel (Age 51)
  • Frank Verwiel M.D., , Director (Age 54)
  • Caroline D. Dorsa, Independent Director (Age 57)
  • Jean-Francois Formela M.D., Independent Director (Age 60)
  • Carl L. Gordon Ph.D., Independent Director (Age 52)

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who owns Intellia Therapeutics stock?

Intellia Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. (11.44%), ORBIMED ADVISORS LLC (5.99%), ORBIMED ADVISORS LLC (4.99%), BlackRock Inc. (4.74%), ARK Investment Management LLC (3.81%) and Farallon Capital Management LLC (3.16%). Company insiders that own Intellia Therapeutics stock include Bros Advisors Lp Baker, Caribou Biosciences, Inc, Carl L Gordon, Institutes For Biomed Novartis, Jean Francois Formela, Nessan Bermingham and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Intellia Therapeutics.

Who sold Intellia Therapeutics stock? Who is selling Intellia Therapeutics stock?

Intellia Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY. Company insiders that have sold Intellia Therapeutics company stock in the last year include Caribou Biosciences, Inc, Institutes For Biomed Novartis, Jean Francois Formela, Nessan Bermingham and Venture Fund Ix LP Atlas. View Insider Buying and Selling for Intellia Therapeutics.

Who bought Intellia Therapeutics stock? Who is buying Intellia Therapeutics stock?

Intellia Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, ARK Investment Management LLC, Shellback Capital LP, Capital Advisors Inc. OK, Goldman Sachs Group Inc., Artal Group S.A., Candriam Luxembourg S.C.A. and Geode Capital Management LLC. Company insiders that have bought Intellia Therapeutics stock in the last two years include Bros Advisors Lp Baker, Carl L Gordon and Institutes For Biomed Novartis. View Insider Buying and Selling for Intellia Therapeutics.

How do I buy Intellia Therapeutics stock?

Shares of Intellia Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intellia Therapeutics' stock price today?

One share of Intellia Therapeutics stock can currently be purchased for approximately $25.95.

How big of a company is Intellia Therapeutics?

Intellia Therapeutics has a market capitalization of $899.98 million and generates $16.48 million in revenue each year. The company earns $-31,630,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. Intellia Therapeutics employs 104 workers across the globe.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 ERIE STREET SUITE 130, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]


MarketBeat Community Rating for Intellia Therapeutics (NTLA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  261
MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intellia Therapeutics (NASDAQ:NTLA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.632.632.75
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.17$30.17$30.17$26.80
Price Target Upside: 64.22% upside64.22% upside37.50% upside66.36% upside

Intellia Therapeutics (NASDAQ:NTLA) Consensus Price Target History

Price Target History for Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ:NTLA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/18/2017OppenheimerReiterated RatingHoldLowView Rating Details
11/5/2017BarclaysReiterated RatingBuyN/AView Rating Details
11/3/2017Credit Suisse GroupBoost Price TargetOutperform$24.00 -> $28.00N/AView Rating Details
10/31/2017Jefferies GroupSet Price TargetBuy -> Buy$36.00 -> $42.00N/AView Rating Details
10/31/2017Leerink SwannBoost Price TargetOutperform$29.00 -> $37.00N/AView Rating Details
9/27/2017WedbushReiterated RatingOurperform$29.00 -> $25.00HighView Rating Details
8/29/2017Chardan CapitalDowngradeBuy -> Neutral$20.00HighView Rating Details
8/1/2017CannReiterated RatingHoldMediumView Rating Details
9/28/2016Janney Montgomery ScottInitiated CoverageBuy$29.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Intellia Therapeutics (NASDAQ:NTLA) Earnings History and Estimates Chart

Earnings by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ NTLA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017Q3 2017($0.50)($0.44)$5.83 million$7.30 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.42)($0.45)$5.83 million$5.90 millionViewN/AView Earnings Details
5/2/2017Q1 2017($0.34)($0.36)$5.30 million$6.22 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.21)($0.31)$5.63 million$5.63 millionViewN/AView Earnings Details
11/1/2016Q3 2016($0.22)($0.22)$4.55 million$4.90 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.10)($0.36)$6.34 million$4.21 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Intellia Therapeutics (NASDAQ:NTLA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.55)($0.52)($0.54)
Q2 20182($0.58)($0.57)($0.58)
Q3 20182($0.51)($0.30)($0.41)
Q4 20182($0.55)($0.33)($0.44)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Intellia Therapeutics (NASDAQ:NTLA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Intellia Therapeutics (NASDAQ NTLA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.80%
Institutional Ownership Percentage: 57.44%
Insider Trades by Quarter for Intellia Therapeutics (NASDAQ:NTLA)
Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ NTLA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/29/2018Caribou Biosciences, Inc.Major ShareholderSell550,645$26.78$14,746,273.10View SEC Filing  
12/12/2017Institutes For Biomed NovartisMajor ShareholderSell1,523,000$18.30$27,870,900.00View SEC Filing  
12/8/2017Nessan BerminghamCEOSell336,783$20.78$6,998,350.74696,000View SEC Filing  
12/6/2017Nessan BerminghamCEOSell111,500$20.34$2,267,910.00696,000View SEC Filing  
7/11/2017Venture Fund Ix L.P. AtlasMajor ShareholderSell150,000$16.24$2,436,000.00View SEC Filing  
3/10/2017Jean Francois FormelaDirectorSell21,132$13.91$293,946.12View SEC Filing  
5/11/2016Bros. Advisors Lp BakerInsiderBuy200,000$18.00$3,600,000.00View SEC Filing  
5/11/2016Carl L GordonDirectorBuy250,000$18.00$4,500,000.00View SEC Filing  
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Intellia Therapeutics (NASDAQ NTLA) News Headlines

Source:
DateHeadline
Analyzing Alkermes (ALKS) & Intellia Therapeutics (NTLA)Analyzing Alkermes (ALKS) & Intellia Therapeutics (NTLA)
www.americanbankingnews.com - February 17 at 5:12 AM
Intellia Therapeutics (NTLA) Stock Rating Upgraded by BidaskClubIntellia Therapeutics (NTLA) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 11 at 8:10 AM
Here's What Pushed Intellia Therapeutics Inc. Up 33.7% in JanuaryHere's What Pushed Intellia Therapeutics Inc. Up 33.7% in January
finance.yahoo.com - February 8 at 4:18 PM
Heres What Pushed Intellia Therapeutics Inc. Up 33.7% in JanuaryHere's What Pushed Intellia Therapeutics Inc. Up 33.7% in January
www.fool.com - February 8 at 1:42 PM
Intellia Therapeutics Inc (NTLA) Given Average Rating of "Hold" by BrokeragesIntellia Therapeutics Inc (NTLA) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 6 at 9:14 AM
Intellia Therapeutics to Present at February Healthcare Investor ConferencesIntellia Therapeutics to Present at February Healthcare Investor Conferences
finance.yahoo.com - February 1 at 9:20 AM
Insider Selling: Intellia Therapeutics Inc (NTLA) Major Shareholder Sells 550,645 Shares of StockInsider Selling: Intellia Therapeutics Inc (NTLA) Major Shareholder Sells 550,645 Shares of Stock
www.americanbankingnews.com - January 30 at 6:14 PM
$9.17 Million in Sales Expected for Intellia Therapeutics Inc (NTLA) This Quarter$9.17 Million in Sales Expected for Intellia Therapeutics Inc (NTLA) This Quarter
www.americanbankingnews.com - January 30 at 6:52 AM
 Brokerages Expect Intellia Therapeutics Inc (NTLA) to Announce -$0.43 EPS Brokerages Expect Intellia Therapeutics Inc (NTLA) to Announce -$0.43 EPS
www.americanbankingnews.com - January 28 at 7:18 AM
Intellia Therapeutics Inc (NTLA) Expected to Post Quarterly Sales of $9.17 MillionIntellia Therapeutics Inc (NTLA) Expected to Post Quarterly Sales of $9.17 Million
www.americanbankingnews.com - January 13 at 11:50 AM
Intellia Therapeutics Inc (NTLA) Receives Average Recommendation of "Hold" from AnalystsIntellia Therapeutics Inc (NTLA) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 12 at 8:02 AM
-$0.43 Earnings Per Share Expected for Intellia Therapeutics Inc (NTLA) This Quarter-$0.43 Earnings Per Share Expected for Intellia Therapeutics Inc (NTLA) This Quarter
www.americanbankingnews.com - January 11 at 8:18 AM
Heres Why Intellia Therapeutics Inc. Fell 14.7% in DecemberHere's Why Intellia Therapeutics Inc. Fell 14.7% in December
www.fool.com - January 4 at 5:15 PM
Here's Why Intellia Therapeutics Inc. Fell 14.7% in DecemberHere's Why Intellia Therapeutics Inc. Fell 14.7% in December
finance.yahoo.com - January 4 at 5:15 PM
Intellia Therapeutics (NTLA) Upgraded to Hold at BidaskClubIntellia Therapeutics (NTLA) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - December 29 at 9:30 AM
Zacks: Brokerages Expect Intellia Therapeutics Inc (NTLA) to Announce -$0.43 EPSZacks: Brokerages Expect Intellia Therapeutics Inc (NTLA) to Announce -$0.43 EPS
www.americanbankingnews.com - December 25 at 5:29 PM
Intellia Therapeutics (NTLA) Names John Leonard, MD, President and CEO - StreetInsider.comIntellia Therapeutics (NTLA) Names John Leonard, MD, President and CEO - StreetInsider.com
www.streetinsider.com - December 18 at 5:14 PM
Intellia Therapeutics (NTLA) Hold Rating Reaffirmed at OppenheimerIntellia Therapeutics' (NTLA) Hold Rating Reaffirmed at Oppenheimer
www.americanbankingnews.com - December 18 at 11:46 AM
Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive OfficerIntellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer
finance.yahoo.com - December 18 at 9:55 AM
Intellia Therapeutics Inc (NTLA) Receives Consensus Rating of "Hold" from BrokeragesIntellia Therapeutics Inc (NTLA) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 18 at 8:18 AM
Intellia Therapeutics (NTLA) Stock Rating Lowered by BidaskClubIntellia Therapeutics (NTLA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - December 16 at 12:44 PM
TheStreet Downgrades Intellia Therapeutics (NTLA) to DTheStreet Downgrades Intellia Therapeutics (NTLA) to D
www.americanbankingnews.com - December 16 at 9:24 AM
Intellia Therapeutics Inc (NTLA) Major Shareholder Sells $27,870,900.00 in StockIntellia Therapeutics Inc (NTLA) Major Shareholder Sells $27,870,900.00 in Stock
www.americanbankingnews.com - December 14 at 2:34 PM
Intellia Therapeutics (NTLA) Receives "Hold" Rating from OppenheimerIntellia Therapeutics (NTLA) Receives "Hold" Rating from Oppenheimer
www.americanbankingnews.com - December 12 at 10:04 AM
Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of ... - GlobeNewswire (press release)Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of ... - GlobeNewswire (press release)
globenewswire.com - December 12 at 10:02 AM
Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology MeetingIntellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting
finance.yahoo.com - December 11 at 10:20 AM
PDL BioPharma (PDLI) & Intellia Therapeutics (NTLA) Critical ReviewPDL BioPharma (PDLI) & Intellia Therapeutics (NTLA) Critical Review
www.americanbankingnews.com - December 11 at 8:08 AM
Zacks: Analysts Expect Intellia Therapeutics Inc (NTLA) Will Announce Quarterly Sales of $9.17 MillionZacks: Analysts Expect Intellia Therapeutics Inc (NTLA) Will Announce Quarterly Sales of $9.17 Million
www.americanbankingnews.com - December 10 at 1:02 PM
Intellia Therapeutics Inc (NTLA) CEO Sells $2,267,910.00 in StockIntellia Therapeutics Inc (NTLA) CEO Sells $2,267,910.00 in Stock
www.americanbankingnews.com - December 8 at 11:16 PM
Insider Selling: Intellia Therapeutics Inc (NTLA) CEO Sells 336,783 Shares of StockInsider Selling: Intellia Therapeutics Inc (NTLA) CEO Sells 336,783 Shares of Stock
www.americanbankingnews.com - December 8 at 8:28 PM
Analyzing Arena Pharmaceuticals (ARNA) and Intellia Therapeutics (NTLA)Analyzing Arena Pharmaceuticals (ARNA) and Intellia Therapeutics (NTLA)
www.americanbankingnews.com - December 7 at 11:34 AM
You Get A Dilution! What About CRISPR ... - Seeking Alpha - Seeking AlphaYou Get A Dilution! What About CRISPR ... - Seeking Alpha - Seeking Alpha
seekingalpha.com - December 7 at 9:53 AM
Intellia Therapeutics, Inc. (NTLA) Receives Consensus Recommendation of "Hold" from AnalystsIntellia Therapeutics, Inc. (NTLA) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 23 at 10:16 AM
$9.17 Million in Sales Expected for Intellia Therapeutics, Inc. (NTLA) This Quarter$9.17 Million in Sales Expected for Intellia Therapeutics, Inc. (NTLA) This Quarter
www.americanbankingnews.com - November 22 at 11:31 AM
Zacks: Brokerages Anticipate Intellia Therapeutics, Inc. (NTLA) to Announce -$0.43 EPSZacks: Brokerages Anticipate Intellia Therapeutics, Inc. (NTLA) to Announce -$0.43 EPS
www.americanbankingnews.com - November 20 at 5:14 AM
Intellia Therapeutics, Inc. (NTLA) Lowered to "Sell" at ValuEngineIntellia Therapeutics, Inc. (NTLA) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - November 15 at 10:22 PM
Intellia Therapeutics, Inc. – Value Analysis (NASDAQ:NTLA) : November 6, 2017Intellia Therapeutics, Inc. – Value Analysis (NASDAQ:NTLA) : November 6, 2017
finance.yahoo.com - November 7 at 7:51 AM
FY2017 EPS Estimates for Intellia Therapeutics, Inc. Boosted by Analyst (NTLA)FY2017 EPS Estimates for Intellia Therapeutics, Inc. Boosted by Analyst (NTLA)
www.americanbankingnews.com - November 6 at 3:48 AM
Intellia Therapeutics, Inc. (NTLA) Price Target Increased to $28.00 by Analysts at Credit Suisse GroupIntellia Therapeutics, Inc. (NTLA) Price Target Increased to $28.00 by Analysts at Credit Suisse Group
www.americanbankingnews.com - November 5 at 8:22 AM
Barclays PLC Reaffirms Buy Rating for Intellia Therapeutics, Inc. (NTLA)Barclays PLC Reaffirms Buy Rating for Intellia Therapeutics, Inc. (NTLA)
www.americanbankingnews.com - November 5 at 7:42 AM
Here's Why Intellia Therapeutics Sank as Much as 17.7% TodayHere's Why Intellia Therapeutics Sank as Much as 17.7% Today
finance.yahoo.com - November 4 at 8:11 AM
Intellia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : NTLA-US : November 3, 2017Intellia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : NTLA-US : November 3, 2017
finance.yahoo.com - November 4 at 8:11 AM
Head to Head Contrast: Intellia Therapeutics (NTLA) & Its CompetitorsHead to Head Contrast: Intellia Therapeutics (NTLA) & Its Competitors
www.americanbankingnews.com - November 3 at 11:20 PM
Intellia Therapeutics, Inc. (NTLA) Expected to Post FY2017 Earnings of ($1.74) Per ShareIntellia Therapeutics, Inc. (NTLA) Expected to Post FY2017 Earnings of ($1.74) Per Share
www.americanbankingnews.com - November 2 at 8:17 AM
Intellia Therapeutics, Inc. to Post FY2017 Earnings of ($1.71) Per Share, Oppenheimer Holdings Forecasts (NTLA)Intellia Therapeutics, Inc. to Post FY2017 Earnings of ($1.71) Per Share, Oppenheimer Holdings Forecasts (NTLA)
www.americanbankingnews.com - November 2 at 8:17 AM
45 Biggest Movers From Yesterday - Benzinga45 Biggest Movers From Yesterday - Benzinga
www.benzinga.com - November 2 at 7:02 AM
Intellia Therapeutics Announces Third Quarter 2017 Financial Results - GlobeNewswire (press release)Intellia Therapeutics Announces Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 2 at 7:02 AM
Intellia Therapeutics, Inc. to Host Earnings CallIntellia Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 1 at 7:00 AM
Intellia Therapeutics Announces Third Quarter 2017 Financial ResultsIntellia Therapeutics Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 7:00 AM
Edited Transcript of NTLA earnings conference call or presentation 31-Oct-17 12:30pm GMTEdited Transcript of NTLA earnings conference call or presentation 31-Oct-17 12:30pm GMT
finance.yahoo.com - November 1 at 7:00 AM

SEC Filings

Intellia Therapeutics (NASDAQ:NTLA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intellia Therapeutics (NASDAQ:NTLA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intellia Therapeutics (NASDAQ NTLA) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.